Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Gautman
Response to Brentuximab Vedotin by Cd30 Expression: Results From Five Trials in Ptcl, Ctcl, and B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
A Phase Ii Trial of Brentuximab Vedotin (Bv) and Lenalidomide (Len) in Relapsed and Refractory (R/R) Cutaneous (Ctcl) and Peripheral (Ptcl) T-Cell Lymphomas: Preliminary Results of a Phase Ii Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Concurrent B-Cell Follicular and Refractory CD30+ Large Cell Transformation of Mycosis Fungoides Responsive to Rituximab and Brentuximab Vedotin
Journal of Blood Disorders & Transfusion
Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Oral Mycosis Fungoides With CD30+ Large Cell Transformation Successfully Treated With Brentuximab Vedotin
JAAD Case Reports
Dermatology
Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia
OncoTargets and Therapy
Oncology
Pharmacology
Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports
Immunopathology, Allergology, Infectology
Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review
Critical Reviews in Oncology/Hematology
Gerontology
Geriatrics
Hematology
Oncology
Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation
Vestnik dermatologii i venerologii
